A federal review is underway that could reclassify 14 peptides into FDA Category 1. This change that may influence how peptide therapies are accessed in the U.S. Here's what experts are In 2023, the FDA deemed 19 peptides too unsafe to be dispensed by compounding pharmacies. Now, under RFK Jr., the agency is poised to reverse itself despite the fact that few 2025 FDA approvals FDA Action Update, January 2026: Approvals, Acceptance, and Clearance NeurologyLive Clinical Neurology News and Neurology Expert Insights The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding spanning categories like Dihexa Capsules 30 x 10mg Bioniq Lab Peptides Made Personal